Market capitalization | $534.14m |
Enterprise Value | $522.67m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 10.00 |
P/S ratio (TTM) P/S ratio | 10.22 |
P/B ratio (TTM) P/B ratio | 13.65 |
Revenue growth (TTM) Revenue growth | -74.04% |
Revenue (TTM) Revenue | $52.29m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Sangamo Therapeutics, Inc. forecast:
8 Analysts have issued a Sangamo Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 52 52 |
74%
74%
|
|
Gross Profit | 42 42 |
77%
77%
|
|
EBITDA | -124 -124 |
43%
43%
|
EBIT (Operating Income) EBIT | -134 -134 |
25%
25%
|
Net Profit | -136 -136 |
45%
45%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.
Head office | United States |
CEO | Alexander Macrae |
Employees | 405 |
Founded | 1995 |
Website | www.sangamo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.